Antibiotic treatment of Gram-positive bone and joint infections

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 6, 2004, Pages 928-935

  Darley, Elizabeth S R ^a   MacGowan, Alasdair P ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Ostemyelitis; Prosthetic joint infections; Septic arthritis; Staphylococci; Streptococci

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBENICILLIN; CEFALOTIN; CEFAMANDOLE; CEFAZOLIN; CEFRADINE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; FLUCLOXACILLIN; FUSIDIC ACID; GENTAMICIN; LINCOMYCIN; LINCOSAMIDE DERIVATIVE; LINEZOLID; METICILLIN; MOXIFLOXACIN; OFLOXACIN; OXACILLIN; PEFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; UNINDEXED DRUG; VANCOMYCIN;

ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG BONE LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG PREFERENCE; DRUG TOLERABILITY; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HUMAN; INFECTIOUS ARTHRITIS; LIVER FAILURE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; MYALGIA; NEPHROTOXICITY; NONHUMAN; OSTEOMYELITIS; PSEUDOMEMBRANOUS COLITIS; REVIEW; STANDARDIZATION; STAPHYLOCOCCUS; STREPTOCOCCUS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BONE DISEASES, INFECTIOUS; CLINICAL TRIALS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; JOINT DISEASES; METHICILLIN RESISTANCE;

EID: 3042623777     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh191     Document Type: Review

References (115)

1. Sax, H. & Lew, D. (1999). Osteomyelitis. Current Infectious Disease Report 1, 261-6.
2. Waldvogel, F. A. & Vasey, H. (1980). Osteomyelitis: the past decade. New England Journal of Medicine 303, 360-70.
3. Goldenberg, D. L. (1998). Septic arthritis. Lancet 351, 197-202.
4. Hamed, K. A., Tam, J. Y. & Prober, C. G. (11996). Pharmacokinetic optimisation of the treatment of septic arthritis. Clinical Pharmacokinetics 31, 156-63.
5. Brause, B. D. (2000). Infections with prostheses in bones and joints. In Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 5th edn (Mandell, G. L., Bennett, J. E. & Dolin, R., Eds). pp. 1196-200. Churchill Livingstone, Philadelphia, PA, USA.
6. Raymond, N. J., Henry, J. & Workowski, K. A. (1995). Enterococcal arthritis: case report and review. Clinical Infectious Diseases 21, 516-22.
7. Oliker, R. & Cunha, B. A. (1999). Streptococcus pneumoniae septic arthritis and osteomyelitis in an HIV-seropositive patient. Heart and Lung 28, 74-6.
8. Allberger, F., Kasten, M. J., Cockerill F. R. et al. (1992). Listeria monocytogenes infection in prosthetic joints. International Orthopaedics 16, 237-9.
9. Massarotti, E. M. & Dinerman, H. (1990). Septic arthritis due to Listeria monocytogenes: report and review of the literature. Journal of Rheumatology 17, 111-3.
10. Raff, M. J. & Melo, J. C. (1978). Anaerobic osteomyelitis. Medicine 57, 83-103.
11. Goldstein, E. J. C. (1991). Bite wounds and infection. Clinical Infectious Diseases 14, 633-40.
12. Cierny, G., Mader, J. T. & Pennick, H. (1985). A clinical staging system of adult osteomyelitis. Contemporary Orthopaedics 10, 17-37.
13. Bell, S. M. (1976). Further observations on the value of oral penicillins in chronic staphylococcal osteomyelitis. Medical Journal of Australia 2, 591-3.
14. Hodgin, U. G. (1975). Antibiotics in the treatment of chronic staphylococcal osteomyelitis. Southern Medical Journal 68, 817-23.
15. Cole, W. G., Dalziel, R. E. & Leitl, S. (1982). Treatment of acute osteomyelitis in childhood. Journal of Bone and Joint Surgery 64B, 218-23.
16. Kaplan, S. L., Mason, E. O. & Feign, R. D. (1982). Clindamycin versus nafcillin or methicillin in the treatment of Staphylococcus aureus osteomyelitis in children. Southern Medical Journal 75, 138-42.
17. Kolyvas, E., Aronheim, G., Marks, M. I. et al. (1980). Oral antibiotic therapy of skeletal infections in children. Pediatrics 65, 8667-71.
18. Rodriguez, W., Ross, S., Khan, W. et al. (1977). Clindamycin in the treatment of osteomyelitis in childrsen. American Journal of Diseases in Children 131, 1088-93.
19. Tetzlaff, T. R., McCracken, G. H. & Nelson, J. D. (1978). Oral antibiotic therapy for skeletal infections of children. II. Therapy of osteomyelitis and suppurative arthritis. Journal of Pediatrics 92, 485-90.
20. Dirschl, D. R. & Almekinders, L. C. (1993). Osteomyelitis. Common causes and treatment recommendations. Drugs 45, 29-43.
21. Mader, J. T., Mohan, D. & Calhoun, J. (1997). A practical guide to the diagnosis and management of bone and joint infections. Drugs 54, 235-64.
22. Cunha, B. (1988). Antibiotics in orthopaedic infections. In Orthopaedic Infection. (Schlossberg, D., Ed.), pp. 156-74. Springer-Verlag, New York, USA.
23. Fitzgerald, R. H., Kelly, P. J., Snyder, R. J. et al. (1978). Penetration of methicillin, oxacillin and cephalothin into bone and synovial tissues. Antimicrobial Agents and Chemotherapy 14, 723-6.
24. Sattar, M. A., Barrett, S. P. & Cawley, M. I. D. (1983). Concentrations of some antibiotics in synovial fluid after oral administration, with some special reference to antistaphylococcal activity. Annals of Rheumatic Diseases 46, 67-74.
25. Cunha, B. A. (1984). The use of penicillins in orthopaedic surgery. Clinical Orthopaedics 190, 36-49.
26. Smith, J. W. & Hasan, M. S. (2000). Bone and joint infections. In Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 5th edn (Mandell, G. L., Bennett, J. E. & Dolin, R., Eds), pp. 1175-82. Churchill Livingstone, Philadelphia, PA, USA.
27. Berendt, A. R. & McLardy-Smith, P. (11999). Prosthetic joint infection. Current Infectious Diseases Reports 1, 267-72.
28. Collins, D. & McKenzie, J. M. (1991). Infections at the site of a hip implant. Clinical Orthopaedics 269, 9-15.
29. Segreti, J., Nelson, J. A. & Trenholme, G. M. (1998). Prolonged suppressive antibiotic therapy for infected orthopaedic prostheses. Clinical Infectious Diseases 27, 711-3.
30. Tattevin, P., Crémieux, A. C., Pottier P. et al. (1999). Prosthetic joint infection: when can prosthesis salvage be considered? Clinical Infectious Diseases 2, 292-5.
31. Moussa, F. W., Anglen, J. O., Gehrke, J. C. et al. (1997). The significance of positive cultures from orthopaedic fixation devices in the absence of clinical infection. American Journal of Orthopaedics 26, 617-20.
32. Atkins, B. L. & Bowler, I. C. J. W. (1998). The diagnosis of large joint sepsis. Journal of Hospital Infection 40, 263-74.
33. Gristina, A. G. & Costerton, J. W. (1985). Bacterial adherence to biomaterials and tissue. Journal of Bone and Joint Surgery 67A, 264-73.
34. Lieberman, J. R., Callaway, G. H., Salvati, E. A. et al. (1994). Treatment of the infected hip arthroplasty with a two-stage reimplantation protocol. Clinical Orthopaedics 301, 205-12.
35. Conlon, C. P. (1996). Outpatient intravenous antibiotic therapy. Journal of Antimicrobial Chemotherapy 38, 557-9.
36. Graninger, W., Wenish, C., Wiesinger, E. et al. (1995). Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis. European Journal of Clinical Microbiology and Infectious Diseases 14, 643-7.
37. Nathwani, D. (1998). Non-inpatient use of teicoplanin. International Journal of Clinical Practice. 52, 577-81.
38. Tice, A. D. (1998). Outpatient parenteral antimicrobial therapy for osteomyelitis. Infectious Disease Clinics of North America 12, 903-17.
39. Brandt, C. M., Sisitrunk, W. W., Duffy, M. C. et al. (1997). Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention. Clinical Infectious Diseases 24, 914-9.
40. Mader, J. T. & Calhoun, J. (2000). Osteomyelitis. In Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 5th edn (Mandell, G. L., Bennett, J. E. & Dolin, R., Eds), pp. 1182-96. Churchill Livingstone, Philadelphia, PA, USA
41. Weinstein, M. P., Stratton, C. W., Hawley, H. B. et al. (1987). Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. American Journal of Medicine 83, 218-22.
42. Black, J., Hunt, T. L., Godley, P. J. et al. (1987). Oral antimicrobial therapy for adults with osteomyelitis or septic arthritis. Journal of Infectious Diseases 155, 968-72.
43. MacGowan, A., McMullin, C., James P. et al. (1997). External quality assessment of the serum bactericidal test: results of a methodology/interpretation questionnaire. Journal of Antimicrobial Chemotherapy 39, 277-84.
44. Norden, C. W. & Shaffer, M. (1983). Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with vancomycin and rifampicin. Journal of Infectious Diseases 147, 352-7.
45. Verklin, R. M. & Mandell, G. L. (1976). Alteration of effectiveness of antibiotics by anaerobiosis. Journal of Laboratory and Clinical Medicine 89, 65-71.
46. Cunha, B. A., Gossling, H. R., Pasternak, H. S. et al. (1977). The penetration characteristics of cefazolin, cephalothin and cephradine into bone in patients undergoing total hip replacement. Journal of Bone and Joint Surgery 59A, 856-60.
47. Smilack, J. D., Flittie, W. H. & Williams, T. W. (1975). Bone concentrations of antimicrobial agents after parenteral administration. Antimicrobial Agents and Chemotherapy 9, 169-71.
48. Summersgill, J. T., Schupp, L. G. & Raff, M. J. (1982). Comparative penetration of metronidazole, clindamycin, chloramphenicol, cefoxitin, ticaricillin and moxalactam into bone. Antimicrobial Agents and Chemotherapy 21, 601-3.
49. Norden, C. W. (1971). Experimental osteomyelitis. II. Therapeutic trial and measurement of antibiotic levels in bone. Journal of Infectious Diseases 124, 565-71.
50. Lovering, A. M., Perez, A. M., Bowker, K. E. et al. (1997). A comparison of the penetration of cefuroxime and cephamandole into bone, fat and haematoma fluid in patients undergoing total hip replacement. Journal of Antimicrobial Chemotherapy 40, 99-104.
51. Dornbusch, K., Carlström, A., Hugo, H. et al. (1977). Antibacterial activity of clindamycin and lincomycin in human bone. Journal of Antimicrobial Chemotherapy 3, 153-60.
52. Gisby, J., Beale, A. S., Bryant, J. E. et al. (1994). Staphylococcal osteomyelitis - a comparison of co-amoxiclav with clindamycin and flucloxacillin in an experimental rat model. Journal of Antimicrobial Chemotherapy 34, 755-64.
53. Mader, J. T., Adams, K. & Morrison, L. (1989). Comparative evaluation of cefazolin and clindamycin in the treatment of experimental Staphylococcus aureus osteomyelitis. Antimicrobial Agents and Chemotherapy 33, 1760-4.
54. Plott, M. A. & Roth, H. (1970). Penetration of clindamycin into synovial fluid. Clinical Pharmacology and Therapeutics 11, 577-80.
55. Schurman, D. J., Johnson, L., Finerman, G. et al. (1975). Antibiotic bone penetration. Clinical Orthopaedics 111, 142-6.
56. Nicholas, P., Meyers, B. R., Levy, R. N. et al. (1975). Concentration of clindamycin in human bone. Antimicrobial Agents and Chemotherapy 8, 220-1.
57. Unsworth, P. F., Heatley, F. W. & Philips, I. (1978). Flucloxacillin in bone. Journal of Clinical Pathology 31, 705-11.
58. Bassey, L. (1992). Oral and parenteral amoxycillin/clavulanic acid in conjunction with surgery for the management of chronic osteomyelitis and severe bone infection. Current Therapeutic Research 52, 922-8.
59. Hooper, J. A. & Wood, A. J. J. (1991). Fluoroquinolone antimicrobial agents. New England Journal of Medicine 324, 384-94.
60. Desplaces, N. & Acar, J. F. (1988). New quinolones in the treatment of joint and bone infections. Reviews in Infectious Diseases 10, Suppl. 1, S179-83.
61. Dellamonica, P., Bernard, E., Etesse, H. et al. (1986). The diffusion of pefloxacin into bone and the treatment of osteomyelitis. Journal of Antimicrobial Chemotherapy 17, Suppl. B, 93-102.
62. Braun, R., Dürig, M. & Harder, F. (1985). Penetration of ciprofloxacin into bone tissues. In Absracts of 14th International Congress of Chemotherapy, Kyoto, Japan. Abstrac P37-85.
63. Giammarellou, H. (1995). Activity of quinolones against Gram-positive cocci: clinical features. Drugs 49, Suppl. 2, 58-66.
64. Lew, D. P. & Waldvogel, F. A. (1997). Osteomyelitis. New England Journal of Medicine 336, 999-1007.
65. Rissing, J. P. (1997). Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones. Clinical Infectious Diseases 25, 1327-33.
66. Gentry, L. O. & Rodriguez, C. G. (1990). Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrobial Agents and Chemotherapy 34, 40-3.
67. Mader, J. T., Cantrell, J. S. & Calhoun, M. D. (1990). Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. Journal of Bone and Joint Surgery 72A, 104-10.
68. Gentry, L. & Rodriguez-Gomez, G. (1991). Ofloxacin versus parenteral therapy for chronic osteomyelitis. Antimicrobial Agents and Chemotherapy 35, 538-41.
69. Blumberg, H. M., Rimland, D., Carroll, D. J. et al. (1991). Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. Journal of Infectious Diseases 16, 1279-85.
70. Drancourt, M., Stein, A., Argenson, J. N. et al. (1993). Oral rifampicin plus ofloxacin for treatment of Staphylococcus-infected orthopaedic implants. Antimicrobial Agents and Chemotherapy 37, 1214-8.
71. Drancourt, M., Stein, A., Argenson, J. N. et al. (1997). Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. Journal of Antimicrobial Chemotherapy 39, 235-40.
72. Blondeau, J. M. (1999). A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones'. Journal of Antimicrobial Chemotherapy 43, Suppl. B, 1-11.
73. Norden, C. W. (1975). Experimental osteomyelitis. IV. Therapeutic trials with rifampicin alone and in combination with gentamicin, sisomycin and cephalothin. Journal of Infectious Diseases 132, 493-9.
74. Yourassowksy, E., Van der Linden, M. P., Lismont, M. J. et al. (1981). Combination of minocycline and rifampicin against methicillin- and gentamicin-resistant Staphylococcus aureus. Journal of Clinical Pathology 34, 559-63.
75. Zinner, S. H., Lagast, H. & Klastersky, J. (1981). Antistaphylococcal activity of rifampicin with other antibiotics. Journal of Infectious Diseases 144, 365-71.
76. Zimmerli, W., Widmer, A., Blatter, M. et al. (1998). Role of rifampicin for treatment of orthopaedic implant-related staphylococcal infections. Journal of the American Medical Association 279, 1537-41.
77. Norden, C. W., Bryant, R., Palmer, D. et al. (1986). Chronic osteomyelitis caused by Staphylococcus aureus: Controlled clinical trial of nafcillin therapy and nafcillin-rifampicin therapy. Southern Medical Journal 79, 947-51.
78. Cox, R. A., Conquest, C., Mallaghan, C. et al. (1995). A major outbreak of methicillin-resistant Staphylococcus aureus caused by a new phage-type (EMRSA-16). Journal of Hospital Infection 29, 87-106.
79. Widmer, A. F., Gaechter, A. & Ochsner, P. E. (1992). Antimicrobial treatment of orthopaedic implant-related infections with rifampicin combinations. Clinical Infectious Diseases 14, 1251-3.
80. Clumeck, N., Marcelis, L., Amiri-Lamraski, M. H. et al. (1984). Treatment of severe staphylococcal infections with a rifampicin-minocycline association. Journal of Antimicrobial Chemotherapy 13, Suppl. C, 17-22.
81. Yzerman, E. P. F., Boelens, H. A. M., Vogl, M. et al. (1998). Efficacy and safety of teicoplanin plus rifampicin in the treatment of bacteraemic infections caused by Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 42, 233-9.
82. Chater, E. H. & Flynn, J. (1972). Fucidin levels in osteomyelitis. Journal of the Irish Medical Association 65, 506-8.
83. Lautenbach, E. E. G., Robinson, R. G. & Koornhof, H. J. (1975). Serum and tissue concentrations of sodium fusidate in patients with chronic osteomyelitis and in normal volunteers. South African Journal of Surgery 13, 21-32.
84. Bailey, E. M., Ryback, M. J. & Kaatz, G. W. (1991). Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrobial Agents and Chemotherapy 35, 1089-92.
85. Wood, M. (1996). The comparative efficacy and safety of teicoplanin and vancomycin. Journal of Antimicrobial Chemotherapy 37, 209-22.
86. Wilson, A. P. R. & Grüneberg, R. N. (1997). Safety. In Teicoplanin: The First Decade. The Medicine Group (Education) Ltd, Abingdon, Oxfordshire, UK, p. 143.
87. Henry, N. K., Roues, M. S., Whitesell, A. L. et al. (1987). Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampicin. American Journal of Medicine 82, Suppl. 4A, 73-5.
88. Graziani, A. L., Lawson, L. A., Gibson, G. A. et al. (1988). Vancomycin concentrations in infected and non-infected human bone. Antimicrobial Agents and Chemotherapy 32, 1320-2.
89. Sheftel, T. G., Mader, J. T., Pennick, J. J. et al. (1985). Methicillin-resistant Staphylococcus aureus osteomyelitis. Clinical Orthopaedics and Related Research 198, 231-9.
90. Fitzpatrick, D. J., Cafferky, M. T., Toner, M. et al. (1986). Osteomyelitis with methicillin resistant Staphylococcus aureus. Journal of Hospital Infection 8, 24-30.
91. Davey, P. G., Rowley, D. R. & Phillips, G. (1992). Teicoplanin - home therapy for prosthetic joint infections. European Journal of Surgery 567, Suppl., 23-5.
92. Greenberg, R. N. (1990). Treatment of bone, joint and vascular-access-associated Gram-positive bacterial infections with teicoplanin. Antimicrobial Agents and Chemotherapy 34, 2392-7.
93. Wilson, A. P. R., Taylor, B., Treasure, T. et al. (1988). Antibiotic prophylaxis in cardiac surgery: serum and tissue levels of teicoplanin, flucloxacillin and tobramycin. Journal of Antimicrobial Chemotherapy 21, 201-12.
94. Grüneberg, R. N. (1997). Anti-Gram-positive agents: what we have and what we would like. Drugs 54, Suppl. 6, 29-38.
95. Marone, P., Concia, E., Andreoni, M. et al. (1990). Treatment of bone and soft tissue infections with teicoplanin. Journal of Antimicrobial Chemotherapy 25, 435-9
96. Bantar, C., Durlach, R., Nicola, F. et al. (1999). Efficacy and pharmacodynamics of teicoplanin given daily during the first 3 days and then on alternate days for methicillin-resistant Staphylococcus aureus infections. Journal of Antimicrobial Chemotherapy 43, 737-40.
97. Eitel, F., Bauernfeind, A. & Lang, E. (1992). Teicoplanin in the therapy of bone and joint infections. Current Therapeutic Research 51, 97-111.
98. Galanakis, N., Giamarellou, H., Moussas, T. et al. (1997). Chronic osteomyelitis caused by multi-resistant Gram-negative bacteria: evaluation of treatment with newer quinolones after prolonged follow-up. Journal of Antimicrobial Chemotherapy 39, 241-6.
99. Le Frock, J. L., Ristuccia, A. M., Ristuccia, P. A. et al. (1992). Teicoplanin in the treatment of bone and joint infections. European Journal of Surgery 567, Suppl., 9-13.
100. Qadri, S. M. H., Halim, M., Ueno, Y. et al. (1994). Susceptibility of methicillin-resistant Staphylococcus aureus to minocycline and other antimicrobials. Chemotherapy 40, 26-9.
101. Yuk, J. H., Dignani, M. C., Harris, R. L. et al. (1991). Minocycline as an alternative antistaphylococcal agent. Reviews in Infectious Diseases 13, 1023-4.
102. Stein, A., Bataille, J. F., Drancourt, M. et al. (1998). Ambulatory treatment of multidrug-resistant Staphylococcus aureus-infected orthopaedic implants with high dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrobial Agents and Chemotherapy 42, 3086-91.
103. Garvin, K. L., Hinrichs, S. H. & Urban, J. A. (1999). Emerging antibiotic-resistant bacteria; their treatment in total joint arthroplasty. Clinical Orthopaedics, 369, 110-23.
104. Linden, P. K. (2000). Quinupristin/dalfopristin: a new therapeutic alternative for the treatment of vancomycin-resistant Enterococcus faecium and other serious Gram-positive infections. Today's Therapeutic Trends 15, 137-53.
105. Drew, R. H., Perfect, J. R., Srinath, L. et al. (2000). Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant or failing prior therapy. Journal of Antimicrobial Chemotherapy 46, 775-84.
106. Summers, M., Misenhimer, G. R. & Anthony, S. J. (2001). Vancomycin-resistant Enterococcus faecium osteomyelitis: successful treatment with quinupristin-dalfopristin. Southern Medical Journal 94, 353-5.
107. Reyzelman, A. M., Van Gils, C. C., Hardin, T. C. et al. (1997). Vancomycin-resistant enterococci osteomyelitis in the foot. A case report. Journal of the American Podiatric Medical Association 87, 434-7.
108. Saleh-Mghir, A., Ameur, N., Muller-Serieys, C. et al. (2002). Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthetic infection. Antimicrobial Agents and Chemotherapy 46, 1122-4.
109. Andrews, J. M. (2001). BSAC standardized disc susceptibility testing method. Journal of Antimicrobial Chemotherapy 48, Suppl. 1, 43-57.
110. Pharmacia and Upjohn Ltd. (2000). Linezolid., Summary of Product Characteristics. Pharmacia and Upjohn Ltd, Milton Keynes, UK.
111. Rana, B., Butcher, I., Grigoris, P. et al. (2002). Linezolid penetration into osteo-articular tissues. Journal of Antimicrobial Chemotherapy 50, 747-50.
112. Bassetti, M., Di Biagio, A., Cenderello, G. et al. (2001). Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA). Journal of Infection 43, 148-9.
113. Melzer, M., Goldsmith, D. & Gransden, W. (2000). Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteraemia. Clinical Infectious Diseases 31, 208-9.
114. Till, M., Wixson, R. L. & Pertel, P. E. (2002). Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium. Clinical Infectious Diseases 15, 1412-4.
115. Patel, R., Piper, K. E., Rouse, M. S. et al. (2000). Linezolid therapy of Staphylococcus aureus experimental osteomyelitis. Antimicrobial Agents and Chemotherapy 44, 3438-40.